1-20 of 30
Carsten Kobe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial

Paul J. Bröckelmann, Sophie Teesink, Lydia Visser, Conrad-Amadeus Voltin, Helen Kaul, Hans Schlösser, Bart-Jan Kroesen, Carsten Kobe, Peter Borchmann, Arjan Diepstra, Wouter Plattel
Journal: Blood
Blood (2024) 144 (Supplement 1): 3044.
https://doi.org/10.1182/blood-2024-201547
Published: 2024
Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Paul J. Bröckelmann, Ina Bühnen, Josée M Zijlstra, Stephan Mathas, Katrin S Roth, Maria Garcia-Marquez, Christian Sillaber, Julia Meissner, Alexander Fossa, Richard Greil, Karolin Trautmann-Grill, Johannes Rosenbrock, Wouter Plattel, Hans A Schlösser, Carsten Kobe, Michael Fuchs, Peter Borchmann, Christian Baues
Journal: Blood
Blood (2024) 144 (Supplement 1): 4428.
https://doi.org/10.1182/blood-2024-202113
Published: 2024
Journal Articles

Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials

Justin Ferdinandus, Helen Kaul, Gundolf Schneider, Michael Fuchs, Hans Theodor Eich, Christian Baues, Johannes Rosenbrock, Katrin S Roth, Alexander Drzezga, Lutz Van Heek, Markus Dietlein, Peter Borchmann, Carsten Kobe
Journal: Blood
Blood (2024) 144 (Supplement 1): 566.
https://doi.org/10.1182/blood-2024-210791
Published: 2024
Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Peter Borchmann, Alden Moccia, Richard Greil, Gundolf Schneider, Mark S. Hertzberg, Valdete Schaub, Andreas Huettmann, Felix Keil, Valdete Schaub, Mathias Hänel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Peter Kamper, Daniel L. Molin, Stefanie Kreissl, Justin Ferdinandus, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, Hans Eich, Christian Baues, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl
Journal: Blood
Blood (2023) 142 (Supplement 1): 3057.
https://doi.org/10.1182/blood-2023-188720
Published: 2023
Journal Articles

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Paul J Bröckelmann, Horst Müller, Sarah Gillessen, Anne Sophie Jacob, Jesko Momotow, Carla Damaschin, Justin Ferdinandus, Xiaoqin Yang, Michael Fuchs, Carsten Kobe, Hans Theodor Eich, Andreas Engert, Peter Borchmann, Bastian von Tresckow
Journal: Blood
Blood (2023) 142 (Supplement 1): 3070.
https://doi.org/10.1182/blood-2023-188622
Published: 2023
Journal Articles

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Clinical Trials & Observations
Dennis A. Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Richard Greil, Alden Moccia, Joseé M. Zijlstra, Bernd Hertenstein, Max S. Topp, Marianne Just, Bastian von Tresckow, Hans-Theodor Eich, Michael Fuchs, Markus Dietlein, Sylvia Hartmann, Andreas Engert, Peter Borchmann
Journal: Blood
Blood (2023) 142 (6): 553–560.
https://doi.org/10.1182/blood.2023019939
Published: 2023
Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Peter Borchmann, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Haenel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M. Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Peter Kamper, Daniel Molin, Stefanie Kreissl, Michael Fuchs, Gundolf Schneider, Andreas Rosenwald, Wolfram Klapper, Hans Eich, Christian Baues, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2022) 140 (Supplement 1): 771–773.
https://doi.org/10.1182/blood-2022-165917
Published: 2022
Journal Articles

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, Bastian von Tresckow
Journal: Blood
Blood (2022) 140 (Supplement 1): 1753–1755.
https://doi.org/10.1182/blood-2022-168846
Published: 2022
Journal Articles

Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study

Dennis A. Eichenauer, Ina Bühnen, Michael Fuchs, Helen Kaul, Carsten Kobe, Sylvia Hartmann, Christian Baues, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2021) 138 (Supplement 1): 2439.
https://doi.org/10.1182/blood-2021-145427
Published: 2021
Journal Articles

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Thomas Pabst, Richard Greil, Dennis A. Eichenauer, Max Topp, Marianne Just, Bernd Hertenstein, Valdete Schaub, Martin Vogelhuber, Josée M Zijlstra, Annette Plütschow, Christian Baues, Andreas Rosenwald, Markus Dietlein, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2021) 138 (Supplement 1): 2438.
https://doi.org/10.1182/blood-2021-152260
Published: 2021
Journal Articles

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Sarah Reinke, Paul J. Bröckelmann, Ingram Iaccarino, Maria Garcia-Marquez, Sven Borchmann, Franziska Jochims, Michaela Kotrova, Karol Pal, Monika Brüggemann, Elena Hartmann, Stephanie Sasse, Carsten Kobe, Stephan Mathas, Martin Soekler, Ulrich Keller, Matthias Bormann, Andreas Zimmermann, Julia Richter, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Hans Schlößer, Michael von Bergwelt-Baildon, Andreas Rosenwald, Andreas Engert, Wolfram Klapper
Journal: Blood
Blood (2020) 136 (25): 2851–2863.
https://doi.org/10.1182/blood.2020008553
Published: 2020
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Paul J Bröckelmann, MD, Helen Goergen, Dipl.-Math., Ulrich Keller, Julia Meissner, MD, Karolin Trautmann, MD, Teresa V Halbsguth, MD, Stephanie Sasse, MD, Martin Sökler, MD, Andrea Kerkhoff, MD, Stephan Mathas, MD, Andreas Hüttmann, MD, Matthias Bormann, MD, Andreas Zimmermann, MD, Michael Fuchs, Bastian von Tresckow, MD, Christian Baues, MD, Andreas Rosenwald, MD, Wolfram Klapper, MD, Carsten Kobe, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-138413
Published: 2020
Journal Articles

AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Stephanie Sasse, MD, Jesko Momotow, MD, Annette Plütschow, Andreas Hüttmann, MD, Nadezda Basara, MD, Christian Koenecke, MD, Sonja Martin, MD, Martin Bentz, MD, Christina Grosse-Thie, MD, Sven Thorspecken, MD, Maike de Wit, MD, Carsten Kobe, MD, Markus Dietlein, MD, Bastian von Tresckow, MD, Michael Fuchs, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-141250
Published: 2020
Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Paul J Bröckelmann, MD, Helen Goergen, Dipl.-Math., Ulrich Keller, MD, Julia Meissner, MD, Rainer Ordemann, MD, Teresa V Halbsguth, MD, Stephanie Sasse, MD, Martin Sökler, MD, Andrea Kerkhoff, MD, Stephan Mathas, MD, Andreas Hüttmann, MD, Matthias Bormann, MD, Andreas Zimmermann, MD, Michael Fuchs, MD, Bastian von Tresckow, Christian Baues, MD, Andreas Rosenwald, MD, Wolfram Klapper, Carsten Kobe, Peter Borchmann, MD PhD, Andreas Engert, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 236.
https://doi.org/10.1182/blood-2019-122406
Published: 2019
Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4020.
https://doi.org/10.1182/blood-2019-123641
Published: 2019
Journal Articles

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe, MD, Hans Eich, MD, Christian Baues, MD, Richard Greil, MD, Stephanie Sasse, MD, Josée M Zijlstra, MD, Andreas Lohri, MD, Andreas Rosenwald, Bastian von Tresckow, MD, Volker Diehl, MD, Georg Kuhnert, Markus Dietlein, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 925.
https://doi.org/10.1182/blood-2018-99-114519
Published: 2018
Journal Articles

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Boris Boell, MD, Alexander Fosså, MD PhD, Helen Goergen, Peter Kamper, Sirpa Leppa, MD Prof, Daniel Molin, Julia Meissner, MD, Ellen Ritter, MD, Jacob H. Christensen, Martin Hutchings, MD, Michael Fuchs, Andreas Engert, MD, Carsten Kobe, MD, Peter Borchmann, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 926.
https://doi.org/10.1182/blood-2018-99-119363
Published: 2018
Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2912.
https://doi.org/10.1182/blood-2018-99-117291
Published: 2018
Journal Articles

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma

Clinical Trials & Observations
Carsten Kobe, Helen Goergen, Christian Baues, Georg Kuhnert, Conrad-Amadeus Voltin, Josée Zijlstra, Otto Hoekstra, Jasmin Mettler, Alexander Drzezga, Andreas Engert, Peter Borchmann, Markus Dietlein
Journal: Blood
Blood (2018) 132 (21): 2273–2279.
https://doi.org/10.1182/blood-2018-05-852129
Published: 2018
Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Peter Borchmann, MD, Helen Goergen, Carsten Kobe, MD, Andreas Lohri, MD, Richard Greil, MD, Dennis A. Eichenauer, Josée M Zijlstra, MD PhD, Jana Markova, MD, Julia Meissner, MD, Michaela Feuring-Buske, PD Dr., Andreas Hüttmann, MD, Judith Dierlamm, MD, Martin Sökler, MD, Stefan W. Krause, MD, Hans Eich, MD, Christian Baues, MD, Stefanie Kreissl, MD, Michael Fuchs, MD, Markus Dietlein, MD, Andreas Engert, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 737.
https://doi.org/10.1182/blood.V130.Suppl_1.737.737
Published: 2017